Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage
hepatocellular carcinoma (HCC). In this review, we summarize recent updates on the use of …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the third leading
cause of cancer‐related death worldwide. HCC exhibits strong inter‐tumor heterogeneity …

Death rates from primary liver cancer (hepatocellular carcinoma [HCC]) have continued to
rise in the United States over the recent decades despite the availability of an increasing …

Simple Summary As a primary hepatic tumor, hepatocellular carcinoma (HCC) is the most
prevalent kind. Recent developments in magnetic resonance imaging (MRI) and computed …

Hepatocellular carcinoma (HCC) is the most common cancer and the second major
contributor to cancer-related mortality. Radiomics, a burgeoning technology that can provide …

Conventional transarterial chemoembolization (cTACE) utilizing ethiodized oil as a
chemotherapy carrier has become a standard treatment for intermediate-stage …

Background Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world
and the third leading cause of cancer-related death. Although the diagnostic scheme of HCC …

Purpose To construct MRI radiomics nomograms that can predict short-term response after
TACE in HCC patients with diameter less than 5 cm. Methods MRI images and clinical data …

Given the frequent co-existence of an aggressive tumor and underlying chronic liver
disease, the management of hepatocellular carcinoma (HCC) patients requires experienced …

The high postoperative recurrence rates in hepatocellular carcinoma (HCC) remain a major
hurdle in its management. Appropriate staging and treatment selection may alleviate the …